Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 76

1.

Angiotensin IV displays only low affinity for native insulin-regulated aminopeptidase (IRAP).

Demaegdt H, De Backer JP, Lukaszuk A, Tóth G, Szemenyei E, Tourwé D, Vauquelin G.

Fundam Clin Pharmacol. 2012 Apr;26(2):194-7. doi: 10.1111/j.1472-8206.2011.00948.x. Epub 2011 Apr 11.

PMID:
21477268
2.

Binding of "AT4 receptor" ligands to insulin regulated aminopeptidase (IRAP) in intact Chinese hamster ovary cells.

Demaegdt H, Gard P, De Backer JP, Lukaszuk A, Szemenyei E, Tóth G, Tourwé D, Vauquelin G.

Mol Cell Endocrinol. 2011 Jun 6;339(1-2):34-44. doi: 10.1016/j.mce.2011.03.005. Epub 2011 Mar 30.

PMID:
21457753
3.

Antagonist-D2S-dopamine receptor interactions in intact recombinant Chinese hamster ovary cells [corrected].

Packeu A, Béghin T, De Backer JP, Vauquelin G.

Fundam Clin Pharmacol. 2010 Jun;24(3):293-303. doi: 10.1111/j.1472-8206.2009.00777.x. Epub 2009 Dec 9. Erratum in: Fundam Clin Pharmacol. 2010 Aug;24(4):531.

PMID:
20015228
4.

Non-competitive interaction between raclopride and spiperone on human D-receptors in intact Chinese hamster ovary cells.

Packeu A, De Backer JP, Vauquelin G.

Fundam Clin Pharmacol. 2010 Jun;24(3):283-91. doi: 10.1111/j.1472-8206.2009.00793.x. Epub 2009 Nov 10.

PMID:
19909349
5.

Selective labeling of IRAP by the tritiated AT(4) receptor ligand [3H]Angiotensin IV and its stable analog [3H]AL-11.

Demaegdt H, Lukaszuk A, De Buyser E, De Backer JP, Szemenyei E, Tóth G, Chakravarthy S, Panicker M, Michotte Y, Tourwé D, Vauquelin G.

Mol Cell Endocrinol. 2009 Nov 13;311(1-2):77-86. doi: 10.1016/j.mce.2009.07.020. Epub 2009 Jul 28.

PMID:
19643163
6.

Translocation of the insulin-regulated aminopeptidase to the cell surface: detection by radioligand binding.

Demaegdt H, Smitz L, De Backer JP, Le MT, Bauwens M, Szemenyei E, Tóth G, Michotte Y, Vanderheyden P, Vauquelin G.

Br J Pharmacol. 2008 Jun;154(4):872-81. doi: 10.1038/bjp.2008.117. Epub 2008 Apr 21.

7.

Antagonist-radioligand binding to D2L-receptors in intact cells.

Packeu A, De Backer JP, Van Liefde I, Vanderheyden PM, Vauquelin G.

Biochem Pharmacol. 2008 Jun 1;75(11):2192-203. doi: 10.1016/j.bcp.2008.03.001. Epub 2008 Mar 14.

PMID:
18436192
8.

Synergistic inhibition of the enzymatic activity of aminopeptidase N by divalent metal ion chelators.

Vanderheyden PM, Demaegdt H, Swales J, Lenaerts PJ, De Backer JP, Vogel LK, Vauquelin G.

Fundam Clin Pharmacol. 2006 Dec;20(6):613-9.

PMID:
17109655
9.

Angiotensin AT4 receptor ligand interaction with cystinyl aminopeptidase and aminopeptidase N: [125I]Angiotensin IV only binds to the cystinyl aminopeptidase apo-enzyme.

Demaegdt H, Lenaerts PJ, Swales J, De Backer JP, Laeremans H, Le MT, Kersemans K, Vogel LK, Michotte Y, Vanderheyden P, Vauquelin G.

Eur J Pharmacol. 2006 Sep 28;546(1-3):19-27. Epub 2006 Jul 21.

PMID:
16919623
10.

Metal ion modulation of cystinyl aminopeptidase.

Laeremans H, Demaegdt H, De Backer JP, Le MT, Kersemans V, Michotte Y, Vauquelin G, Vanderheyden PM.

Biochem J. 2005 Aug 15;390(Pt 1):351-7.

11.

Ligand binding and functional properties of human angiotensin AT1 receptors in transiently and stably expressed CHO-K1 cells.

Le MT, De Backer JP, Hunyady L, Vanderheyden PM, Vauquelin G.

Eur J Pharmacol. 2005 Apr 18;513(1-2):35-45. Epub 2005 Apr 12.

PMID:
15878707
12.

AT1 receptor antagonists.

Verheijen I, Vanderheyden PM, De Backer JP, Vauquelin G.

Curr Med Chem Cardiovasc Hematol Agents. 2004 Jan;2(1):69-77. Review.

PMID:
15320808
13.

Synergistic modulation of cystinyl aminopeptidase by divalent cation chelators.

Demaegdt H, Laeremans H, De Backer JP, Mosselmans S, Le MT, Kersemans V, Michotte Y, Vauquelin G, Vanderheyden PM.

Biochem Pharmacol. 2004 Sep 1;68(5):893-900.

PMID:
15294452
14.

Endogenous cystinyl aminopeptidase in Chinese hamster ovary cells: characterization by [125I]Ang IV binding and catalytic activity.

Demaegdt H, Vanderheyden P, De Backer JP, Mosselmans S, Laeremans H, Le MT, Kersemans V, Michotte Y, Vauquelin G.

Biochem Pharmacol. 2004 Sep 1;68(5):885-92.

PMID:
15294451
15.

A two-state model of antagonist-AT1 receptor interaction: further support by binding studies at low temperature.

Verheijen I, De Backer JP, Vanderheyden P, Vauquelin G.

Biochem Pharmacol. 2003 Apr 15;65(8):1339-41.

PMID:
12694874
16.

Antagonist interaction with endogenous AT(1) receptors in human cell lines.

Verheijen I, Vanderheyden PM, De Backer JP, Bottari S, Vauquelin G.

Biochem Pharmacol. 2002 Oct 15;64(8):1207-14.

PMID:
12234601
17.

Distinct binding properties of the AT(1) receptor antagonist [(3)H]candesartan to intact cells and membrane preparations.

Fierens FL, Vanderheyden PM, Roggeman C, Vande Gucht P, De Backer JP, Vauquelin G.

Biochem Pharmacol. 2002 Apr 1;63(7):1273-9.

PMID:
11960603
18.

Effects of BIBP3226 and BIBP3435 on cytosolic calcium in neuropeptide Y Y1 receptor-transfected Chinese hamster ovary cells and wild type CHO-K1 cells.

Van Liefde, Vanderheyden PM, De Backer JP, Ebinger G, Vauquelin G.

J Recept Signal Transduct Res. 2001 Feb;21(1):11-23.

PMID:
11693170
19.

Role of basic amino acids of the human angiotensin type 1 receptor in the binding of the non-peptide antagonist candesartan.

Vauquelin G, Fierens FL, Gáborik Z, Le Minh T, De Backer JP, Hunyady L, Vanderheyden PM.

J Renin Angiotensin Aldosterone Syst. 2001 Mar;2(1_suppl):S32-S36. doi: 10.1177/14703203010020010501.

PMID:
28095235
20.

A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists.

Vauquelin G, Morsing P, Fierens FL, De Backer JP, Vanderheyden PM.

Biochem Pharmacol. 2001 Feb 1;61(3):277-84.

PMID:
11172731

Supplemental Content

Loading ...
Support Center